Cargando…

TUSC2 immunogene enhances efficacy of chemo-immuno combination on KRAS/LKB1 mutant NSCLC in humanized mouse model

KRAS/LKB1 (STK11) NSCLC metastatic tumors are intrinsically resistant to anti-PD-1 or PD-L1 immunotherapy. In this study, we use a humanized mouse model to show that while carboplatin plus pembrolizumab reduce tumor growth moderately and transiently, the addition of the tumor suppressor gene TUSC2,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Meraz, Ismail M., Majidi, Mourad, Shao, RuPing, Meng, Feng, Ha, Min Jin, Shpall, Elizabeth, Roth, Jack A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8873264/ https://www.ncbi.nlm.nih.gov/pubmed/35210547 http://dx.doi.org/10.1038/s42003-022-03103-7

Ejemplares similares

The Tumor Suppressor Gene TUSC2 (FUS1) Sensitizes NSCLC to the AKT Inhibitor MK2206 in LKB1-dependent Manner
por: Meng, Jieru, et al.
Publicado: (2013)

TUSC2 downregulates PD-L1 expression in non-small cell lung cancer (NSCLC)
por: Cao, Xiaobo, et al.
Publicado: (2017)

TUSC2(FUS1)-erlotinib Induced Vulnerabilities in Epidermal Growth Factor Receptor(EGFR) Wildtype Non-small Cell Lung Cancer(NSCLC) Targeted by the Repurposed Drug Auranofin
por: Xiaobo, Cao, et al.
Publicado: (2016)

LKB1/KRAS mutant lung cancers constitute a genetic subset of NSCLC with increased sensitivity to MAPK and mTOR signalling inhibition
por: Mahoney, C L, et al.
Publicado: (2009)

The hexosamine biosynthesis pathway is a targetable liability in KRAS/LKB1-mutant lung cancer
por: Kim, Jiyeon, et al.
Publicado: (2020)

Treating KRAS-mutant NSCLC: latest evidence and clinical consequences
por: Garrido, Pilar, et al.
Publicado: (2017)

Clinicopathologic Characteristics and Outcomes for Patients With KRAS G12D-Mutant NSCLC
por: Cooper, Alissa J., et al.
Publicado: (2022)

CPS1 maintains pyrimidine pools and DNA synthesis in KRAS/LKB1-mutant lung cancer cells
por: Kim, Jiyeon, et al.
Publicado: (2017)

Targeting PGM3 as a Novel Therapeutic Strategy in KRAS/LKB1 Co-Mutant Lung Cancer
por: Lee, Hyunmin, et al.
Publicado: (2022)

miRNA-mediated TUSC3 deficiency enhances UPR and ERAD to promote metastatic potential of NSCLC
por: Jeon, Young-Jun, et al.
Publicado: (2018)

Kras mutations increase telomerase activity and targeting telomerase is a promising therapeutic strategy for Kras-mutant NSCLC
por: Liu, Weiran, et al.
Publicado: (2016)

The pseudogene TUSC2P promotes TUSC2 function by binding multiple microRNAs
por: Rutnam, Zina Jeyapalan, et al.
Publicado: (2014)

Phenformin enhances the therapeutic effect of selumetinib in KRAS-mutant non-small cell lung cancer irrespective of LKB1 status
por: Zhang, Jun, et al.
Publicado: (2017)

Author Correction: 3-Phosphoinositide-dependent kinase 1 drives acquired resistance to osimertinib
por: Meraz, Ismail M., et al.
Publicado: (2023)

3-Phosphoinositide-dependent kinase 1 drives acquired resistance to osimertinib
por: Meraz, Ismail M., et al.
Publicado: (2023)

Evaluation of cell surface reactive immuno-adjuvant in combination with immunogenic cell death inducing drug for in situ chemo-immunotherapy
por: Walters, Adam A., et al.
Publicado: (2020)

KRAS/LKB1 and KRAS/TP53 co-mutations create divergent immune signatures in lung adenocarcinomas
por: Gu, Meichen, et al.
Publicado: (2021)

Altered Transcriptional Control Networks with Trans-Differentiation of Isogenic Mutant-KRas NSCLC Models
por: Haley, John A., et al.
Publicado: (2014)

Targeted inhibition of glutamine metabolism enhances the antitumor effect of selumetinib in KRAS-mutant NSCLC
por: Xia, Meng, et al.
Publicado: (2020)

LKB1: Can We Target an Hidden Target? Focus on NSCLC
por: Ndembe, Gloriana, et al.
Publicado: (2022)

Chemo-/immuno-/radiotherapy combination in treatment of solid cancer
por: Käsmann, Lukas, et al.
Publicado: (2019)

Mechanisms of FUS1/TUSC2 deficiency in mesothelioma and its tumorigenic transcriptional effects
por: Ivanova, Alla V, et al.
Publicado: (2009)

Comparative metabolomics profiling of isogenic KRAS wild type and mutant NSCLC cells in vitro and in vivo
por: Brunelli, Laura, et al.
Publicado: (2016)

Inhibition of lncRNA PART1 Chemosensitizes Wild Type but Not KRAS Mutant NSCLC Cells
por: Chen, Shu-Chen, et al.
Publicado: (2020)

Metformin and salinomycin as the best combination for the eradication of NSCLC monolayer cells and their alveospheres (cancer stem cells) irrespective of EGFR, KRAS, EML4/ALK and LKB1 status
por: Xiao, Zhiguang, et al.
Publicado: (2014)

Exogenous Restoration of TUSC2 Expression Induces Responsiveness to Erlotinib in Wildtype Epidermal Growth Factor Receptor (EGFR) Lung Cancer Cells through Context Specific Pathways Resulting in Enhanced Therapeutic Efficacy
por: Dai, Bingbing, et al.
Publicado: (2015)

Mild Oxidative Stress Reduces NRF2 SUMOylation to Promote Kras/Lkb1/Keap1 Mutant Lung Adenocarcinoma Cell Migration and Invasion
por: Xu, Jiaqian, et al.
Publicado: (2020)

Base excision repair-mediated resistance to cisplatin in KRAS(G12C) mutant NSCLC cells
por: Caiola, Elisa, et al.
Publicado: (2015)

Efficacy of immunotherapy in KRAS-mutant advanced NSCLC: A real-world study in a Chinese population
por: Peng, Lixiu, et al.
Publicado: (2023)

STK11 (LKB1) mutations in metastatic NSCLC: Prognostic value in the real world
por: Shire, Norah J., et al.
Publicado: (2020)

TUSC2P suppresses the tumor function of esophageal squamous cell carcinoma by regulating TUSC2 expression and correlates with disease prognosis
por: Liu, Fengqiong, et al.
Publicado: (2018)

Inhibition of autophagy and MEK promotes ferroptosis in Lkb1-deficient Kras-driven lung tumors
por: Bhatt, Vrushank, et al.
Publicado: (2023)

Parenteral Nanoemulsions Loaded with Combined Immuno- and Chemo-Therapy for Melanoma Treatment
por: Monge, Chiara, et al.
Publicado: (2022)

TEAD Inhibitors Sensitize KRAS(G12C) Inhibitors via Dual Cell Cycle Arrest in KRAS(G12C)-Mutant NSCLC
por: Tammaccaro, Salvina Laura, et al.
Publicado: (2023)

KRAS in NSCLC: State of the Art and Future Perspectives
por: Cascetta, Priscilla, et al.
Publicado: (2022)

A CRISPR screen identifies MAPK7 as a target for combination with MEK inhibition in KRAS mutant NSCLC
por: Dompe, Nicholas, et al.
Publicado: (2018)

Abemaciclib in Combination With Pembrolizumab for Stage IV KRAS-Mutant or Squamous NSCLC: A Phase 1b Study
por: Pujol, Jean-Louis, et al.
Publicado: (2021)

Statin-mediated inhibition of RAS prenylation activates ER stress to enhance the immunogenicity of KRAS mutant cancer
por: Nam, Gi-Hoon, et al.
Publicado: (2021)

AXL targeting restores PD-1 blockade sensitivity of STK11/LKB1 mutant NSCLC through expansion of TCF1(+) CD8 T cells
por: Li, Huiyu, et al.
Publicado: (2022)

Escaping KRAS: Gaining Autonomy and Resistance to KRAS Inhibition in KRAS Mutant Cancers
por: Adachi, Yuta, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_rrndvult08iu1fh0o97rthh73o